In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 15.5 above Aclarion Inc average.

Within Medical Laboratories industry 2 other companies have achieved higher Quick Ratio than Aclarion Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 162 to 310.

Explain Quick Ratio?
How much Cash & cash equivalents ACON�s has?
What are ACON�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACON Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	86.16 %	41.11 %	-27.41 %	5.68 %	-60.99 %
Y / Y Cash & cash equivalent Change	26.98 %	28.84 %	2548.63 %	764.37 %	993.7 %
Quick Ratio MRQ	15.5	19.27	14.35	16.21	22.73
ACON's Total Ranking	# 310	# 162	# 148	# 180	# 103
Seq. Current Liabilities Change	6.52 %	17.78 %	19.67 %	23.98 %	-19.25 %
Seq. Cash & cash equivalent Change	-14.31 %	58.17 %	5.95 %	-11.57 %	-13.05 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 3
Healthcare Sector	# 98
Overall Market	# 310

Quick Ratio Statistics
High	Average	Low
22.73	6.46	0.01
(Jun 30 2025)		(Mar 31 2022)

Financial Statements
Aclarion Inc 's Current Liabilities	$ 1 Millions	Visit ACON's Balance sheet
Aclarion Inc 's Cash & cash equivalent	$ 16 Millions	Visit ACON's Balance sheet
Source of ACON's Sales		Visit ACON's Sales by Geography

Cumulative Aclarion Inc 's Quick Ratio

ACON's Quick Ratio for the trailling 12 Months

ACON Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	16.08 %	-22.05 %	-37.06 %	-51.94 %	-61.43 %
Y / Y Cash & cash equivalent TTM Growth	99.88 %	211.99 %	904.38 %	598.25 %	553.8 %
Quick Ratio TTM	16.41	17.87	18.19	12.63	9.53
Total Ranking TTM	# 2966	# 2897	# 1994	# 2663	# 2646
Seq. Current Liabilities TTM Growth	15.75 %	10.26 %	-10.14 %	1.22 %	-22.27 %
Seq. Cash & cash equivalent TTM Growth	6.27 %	8.35 %	29.37 %	34.18 %	65.88 %

Quick ratio ranking by company, industry and sector >> Back to ACON Financial Strength Comparisons >> Go to Compare ACON Quick Ratio to its Competitors

News about Aclarion Inc Quick Ratio

Aclarion Announces Pricing of $3.0 Million Public Offering Amidst Financial Concerns

Aclarion, Inc. Announces Pricing of Public Offering Amidst Financial Concerns
BROOMFIELD, CO Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in leveraging biomarkers and proprietary augmented intelligence algorithms, recently announced the pricing of its public offering of 5,175,000 units. Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant allowing the purchase of one share of common stock. The public offering price has been set at $0.58 per unit.
The company s decision to proceed with a public offering comes at a crucial time as Aclarion faces challenges related to its financial health. In the third quarter of 2023, the company witnessed an increase in current liabilities, causing its Quick Ratio to fall to a concerning 0.07, well below the Aclarion Inc average Quick Ratio. Comparatively, 38 other companies within the industry have reported higher Quick Ratios during the same period.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $1.05 millions, cumulative Quick Ratio decreased to 16.41 above the ACON average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 29 other companies have achieved higher Quick Ratio than Aclarion Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2897 to 2966.

Explain Quick Ratio?
How much Cash & cash equivalents ACON�s has?
What are ACON�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 30
Healthcare Sector	# 808
Within the Market	# 2966

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.19	5.79	0.27
(Dec 31 2025)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Aclarion Inc	15.50	$ 16.285 Millions	$ 1.051 Millions
Miragen Therapeutics Inc	12.67	$ 981.530 Millions	$ 77.484 Millions
Maxcyte inc	10.68	$ 105.690 Millions	$ 9.895 Millions
Grail Inc	10.29	$ 859.755 Millions	$ 83.542 Millions
Absci Corp	10.12	$ 201.142 Millions	$ 19.878 Millions
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions

Date modified: 2026-09-05T14:52:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.